82 Pharmacokinetic–pharmacodynamic modeling of the effect of GDC-0152, a selective antagonist of the inhibitor of apoptosis (IAP) proteins, on monocyte chemotactic protein-1 (MCP-1) indicates species differences in MCP-1 response
Fairbrother W, Wong H, Budha N, Blackwood B, Gould S, Erickson R, LoRusso P, Eckhardt S, Wagner A, Chan I. 82 Pharmacokinetic–pharmacodynamic modeling of the effect of GDC-0152, a selective antagonist of the inhibitor of apoptosis (IAP) proteins, on monocyte chemotactic protein-1 (MCP-1) indicates species differences in MCP-1 response. European Journal Of Cancer Supplements 2010, 8: 34. DOI: 10.1016/s1359-6349(10)71787-0.Peer-Reviewed Original ResearchHyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor.
Busaidy N, Kurzrock R, LoRusso P, Owens A, Chen H, Doyle L, Zhang J, Lawhorn K, Chandhasin C, Naing A. Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia in a phase I trial of the combination of an mTOR inhibitor and IGF-1 receptor inhibitor. Journal Of Clinical Oncology 2010, 28: 2597-2597. DOI: 10.1200/jco.2010.28.15_suppl.2597.Peer-Reviewed Original Research